Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Mar 1.

Published in final edited form as: Cancer Immunol Res. 2016 Feb 3;4(3):225–233. doi: 10.1158/2326-6066.CIR-15-0200-T

Table 2.

Correlation of increased antibody response to PSMC5, MYPT1 and TFRC post-vaccination with response to vaccine.

		Number of patients

		Total	Increase	Decrease	p-value^*
PSMC5	Responders	12	8/12 (67%)	1/12(8%)	< 0.05
PSMC5	Non-responders	12	2/12 (17%)	2/12 (17%)	< 0.05

MYPT1	Responders	12	9/12 (75%)	1/12(8%)	= 0.3
MYPT1	Non-responders	12	5/12 (42%)	4/12 (33%)	= 0.3

TFRC	Responders	12	8/12 (67%)	1/12(8%)	< 0.05
TFRC	Non-responders	12	2/12 (17%)	2/12 (17%)	< 0.05

Responders are patients with DFS > 3 years (Group A) whereas non-responders are patients with DFS < 3 years (Group B).

^*

Fishers exact test